Infectious clone of human parvovirus B19 and methods
The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.
1. An isolated infectious parvovirus B19 clone comprising a parvovirus B19 genome in a replicable vector, wherein the genome comprises a polynucleotide encoding a parvovirus B19 VP1, a parvovirus B19 VP2, a parvovirus B19 nonstructural (NS) protein, a parvovirus B19 11-kDa protein, and a parvovirus B19 inverted terminal repeat (ITR) located at a 5′ end and a 3′ end of the genome, wherein the parvovirus ITR located at the 5′ end comprises a sequence of SEQ ID NO:1 or SEQ ID NO:2, and the parvovirus ITR located at the 3′ end comprises a sequence of SEQ ID NO:1 or SEQ ID NO:2.
2. The isolated infectious parvovirus B19 clone of claim 1 , wherein parvovirus B19 genome is a full-length genome.
3. The isolated infectious parvovirus B19 clone of claim 1 , wherein the parvovirus B19 genome comprises a polynucleotide having at least 98% sequence identity to SEQ ID NO:5 or SEQ ID NO:24.
4. The isolated infectious parvovirus B19 clone of claim 3 , wherein the parvovirus B19 genome comprises a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:5.
5. An isolated cell comprising the infectious clone of parvovirus B19 of claim 1 .
6. The infectious parvovirus clone of claim 1 , wherein the genome further comprises at least one alteration in the genome to encode a change in a restriction site to form an altered restriction site so that the site is cleaved by a different restriction enzyme or is eliminated.
7. The infectious clone of claim 6 , wherein the altered restriction site is cleaved by restriction enzyme Dde.
8. The infectious clone of claim 6 , wherein the altered restriction site eliminates a restriction site.
9. A composition comprising an infectious clone of claim 1 , and a carrier.